Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Jurnal Health Sains Respiratory Science Bioscientia Medicina : Journal of Biomedicine and Translational Research
Febrina, Nidya
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Idiopathic Pulmonary Fibrosis: A Narrative Literature Review Febrina, Nidya; Dewi Wijaya
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1052

Abstract

Idiopathic pulmonary fibrosis is a chronic progressive interstitial lung disease (ILD) with unknown causes. Male gender, age > 60 years, history of smoking with symptoms of dry cough and progressive chronic shortness of breath are typical clinical findings in this patient. The diagnosis is made based on a combination of radiological findings in the form of a pattern consistent with usual interstitial pneumonia (UIP) and/or histopathology with the exclusion of other causes of ILD. Treatment includes pharmacological and non-pharmacological therapy in the form of pulmonary rehabilitation, psychosocial support, and lung transplantation. Anti-fibrosis pharmacological therapy, namely nintedanib and pirfenidone, has been proven to slow the progression of pulmonary fibrosis and reduce mortality. The relatively low average survival rate of 3-4 years after the diagnosis is made makes this disease have a poor prognosis and requires adequate identification and treatment in order to reduce morbidity, mortality and improve the quality of life of sufferers.
Long COVID-19: Multidisciplinary Approach and Pulmonary Fibrosis Sequelae Febrina, Nidya; Yovi, Indra
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.140

Abstract

COVID-19 patients may experience a persistent condition of post-COVID-19 infection, which is known as the long-COVID phenomenon or post-acute sequelae of SARS-CoV-2 infection (PASC) or post-acute COVID-19 syndrome (PACS) with long-term sequelae characteristics that stay after the convalescent period of COVID-19 disease. The most common clinical symptoms found within 5 weeks post-infection were fatigue (12.7%), cough (12.4%), headache (11.1%), loss of sense of taste or smell (10.4%), and muscle pain (8.8%). Women have a slightly higher prevalence than men, with a value of 23.6% and 20.7%, respectively, which are dominated by 35-49 years old (26.8%), 50-69 years old (26.1%), and 25-34 years old (24.9%). Pulmonary fibrosis sequelae in COVID-19 occur due to the destruction of the alveolar epithelium and the formation of active myofibroblast foci, causing excessive accumulation of extracellular matrix in lung tissue. Long COVID management requires a multidisciplinary approach, including health workers and the wider community, as well as systematic assessment management. The recommended therapy includes pharmacological (symptomatic, micronutrients, antibiotics, and anti-inflammatory) and non-pharmacological (medical and psychosocial rehabilitation). This review aims to summarize the long COVID and multidisciplinary approach to improve the patient's quality of life.
Characteristics of Bacteriological Pulmonary Tuberculosis Cases for The January – August 2021 Period at Arifin Achmad Hospital, Riau Province Lasmaria, Rohani; Febrina, Nidya; Simanjutak, Arya Maganda
Jurnal Health Sains Vol. 4 No. 12 (2023): Journal Health Sains
Publisher : Syntax Corporation Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46799/jhs.v4i12.1153

Abstract

Background: Mycobacterium tuberculosis, which causes TB, is a deadly disease that mostly affects the lungs. Surveys revealed that although there was significant variance, the estimated incidence of bacteriologically proven pulmonary TB per 100 000 people aged 15 or older was high in several countries. With multisectoral action and responsibility to address the larger causes that influence the TB epidemic and the socioeconomic effect of TB, knowing and comprehending the sociodemographic features of tuberculosis can serve as a milestone in the End TB Strategy by 2035. Methods: Descriptive cross-sectional methodology was employed in this study to collect data. 154 samples were collected over the course of eight months in accordance with the inclusion criteria; the findings are displayed as a distribution table. Results: The study's results showed that of 154 samples, patients with positive bacteriological TB were more likely to be men than women, to be in their prime working years, to be HIV-negative and to be medication sensitive. Discussion: Knowing characteristics of patients with pulmonary tuberculosis in important due to prevent higher risk of drug resistant, non-adherence treatment and mortality
Idiopathic Pulmonary Fibrosis: A Narrative Literature Review Febrina, Nidya; Dewi Wijaya
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i8.1052

Abstract

Idiopathic pulmonary fibrosis is a chronic progressive interstitial lung disease (ILD) with unknown causes. Male gender, age > 60 years, history of smoking with symptoms of dry cough and progressive chronic shortness of breath are typical clinical findings in this patient. The diagnosis is made based on a combination of radiological findings in the form of a pattern consistent with usual interstitial pneumonia (UIP) and/or histopathology with the exclusion of other causes of ILD. Treatment includes pharmacological and non-pharmacological therapy in the form of pulmonary rehabilitation, psychosocial support, and lung transplantation. Anti-fibrosis pharmacological therapy, namely nintedanib and pirfenidone, has been proven to slow the progression of pulmonary fibrosis and reduce mortality. The relatively low average survival rate of 3-4 years after the diagnosis is made makes this disease have a poor prognosis and requires adequate identification and treatment in order to reduce morbidity, mortality and improve the quality of life of sufferers.
Co-Authors Dewi Wijaya INDRA YOVI Lasmaria, Rohani Simanjutak, Arya Maganda